Price control on monopoly drugs

1640. SHRI SANTOSH KUMAR SAHU: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) whether it is a fact that his Ministry has received a number of representations for inclusion of drugs under price control having monopoly productions;

(b) whether his Ministry has examined the details of those drugs;

(c) what are the names of producers of each drug, value and quantity of production during the last three years, year-wise of each drug;

(d) what is the leader brand of formulation based on each drug and what is the market share enjoyed by each;

(e) whether it is a fact that number of drugs either totally imported or monopoly produced having sales turn over of more than rupees fifty lacs per annum were excluded from price control;

(f) what are the details of such instances which came to the notice of his Ministry; and

(g) what steps have been taken to establish accountability for these omissions?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) to (g) A number of representations have been received by the Government for inclusion of certain drugs under price control. Government have constituted a Standing Committee to look into various aspects concerning DPCO, 1987 including representations received for exclusion/inclusion of certain drugs under Scheduled Categories. 21 drugs have already been included in Category II of DPCO, 1987 on 27.2.1990.

Concentration aspects for Price Control

1641. SHRI JAGESH DESAI: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state.

(a) what is the meaning of the term concentration as used by Kelkar Committee with reference to criteria V of the report on identification of drugs for Category II of price control;

(b) whether the committee applied this criteria to Nandrolone Phenyl Propionate, Methdilazine, Diphenhydramine, and several other drugs;

(c) if not, what steps have been taken to rectify the situation; and

(d) what are the names of drugs still exempted from price control which fits into the definition of concentration adopted by Kelkar Committee and what action has been taken by his Ministry in this regard?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) It is already explained in the Report of the Kelkar Committee, copies of which are available in the Parliament Library.

(b) to (d) Although the Main as well as Supplementary Report of the Kelkar Committee explain reasons for inclusion/exclusion of certain drugs under DPCO, 1987, Government have received a number of representations on the subject Government have constituted a Standing Committee to look into these aspects.

Bringing price decontrolled drugs under price control

1642. SHRI CHANDRIKA PRASAD TRIPATHI: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) whether it is a fact that his Ministry in its press release issued on the 8th March, 1990 indicated that all those drugs which do not fulfil exclusion criteria laid down by Kelkar Committee would be shortly brought

under price control after examination by his Ministry without referring to any expert group;

(b) if so, whether it is a fact that Calcium Salts, Nandrolone Phenyl Propionate, Nandrolone Deconate, Ethyl Estranol, Cyclandelate, Nasterolone, Norethisterone, Allyloestrenol, Flurbiprofen and Methdilazine Hcl do not fulfil any of the exclusion criteria;

(c) whether it is also a fact that his Ministry received a number of representations for their inclusion under price control; and

(d) by when the verifications and examination would be completed and these drugs would be brought under price control?

THE MINISTER FO PETROLUEM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) to (d) The intention of the Government to take decision after due examination, is amply clear in the Press Note. And Government have constituted a Standing Committee to consider all matters connected with the review of Drugs (Prices Control) Order, 1987 including representations made on various policy issues concerning DPCO, 1987, inclusion/exclusion of drugs in the Scheduled Categories etc. This Standing Committee will be assisted by three Expert Groups. The report of these Expert Groups will be considered by the Standing Committee for making final recommendation on the oasis of which Government will take decisions. The Expert Groups and the Standing Committee will meet once in three months or as and when required.

Development of hospital in Andhra Pradesh

1643. DR. NARREDDY THULASI REDDY:

PROF. C. LAKSHMANNA:

SHRI TALARI MANOHAR:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that the Government of Andhra Pradesh has sent to the Central Government a project report regarding development of a secondary grade hospital in Andhra Pradesh costing Rs. 127 crores with foreign assistance;

(b) if so, what are the salient features of the above report; and

(c) what action has been taken by Central Government on this report?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI NILAMANI ROUTRAY): (a) to (c) The information is being collected and will be laid on the Table of Sabha.

Phased decontrol of drugs

1644. SHRI CHATURANAN MISHRA:

SHRI N. E. BALARAM:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) whether Government are considering a proposal for phased decontrol of all drugs; and

(b) if so, what are the details thereof and reasons therefor?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) No, Sir.

(b) Does not arise.

Health care education

1645. SHRI CHATURANAN MISHRA:

SHRI N. E. BALARAM:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether Government's attention has been drawn to the news-item which appeared in the Statesman of the 7th March, 1990 captioning health care under utilised; and